This is a preview of subscription content, log in via an institution to check access.
Notes
hormone receptor-positive/human epidermal receptor 2-negative
The study was funded by Novartis.
Reference
Mistry R, et al. Cost-Effectiveness of Ribociclib plus Letrozole Versus Palbociclib plus Letrozole and Letrozole Monotherapy in the First-Line Treatment of Postmenopausal Women with HR+/HER2- Advanced or Metastatic Breast Cancer: A U.S. Payer Perspective. Journal of Managed Care and Specialty Pharmacy 24: No. 6, Jun 2018. Available from: URL: https://www.jmcp.org/doi/pdf/10.18553/jmcp.2018.24.6.514
Rights and permissions
About this article
Cite this article
Ribociclib + letrozole good choice in advanced breast cancer. PharmacoEcon Outcomes News 805, 30 (2018). https://doi.org/10.1007/s40274-018-5032-x
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-018-5032-x